Market Research Logo

Global Diabetic Therapeutic Market 2017-2021

About Diabetic Therapeutic

The global diabetic therapeutic market is growing at a high pace owing to the increase in the prevalence of diabetes globally. The top countries with high prevalence of diabetes are China, India, the US, Brazil, Russia, Mexico, Indonesia, Egypt, Japan, and Bangladesh. It is estimated that more than 1.5 million deaths occur due to diabetes worldwide each year.

Technavio’s analysts forecast the global diabetic therapeutic market to grow at a CAGR of 7.55% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global diabetic therapeutic market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of branded drugs, generics, and biosimilars used for the treatment of diabetes. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period..

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Diabetic Therapeutic Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • AstraZeneca
  • Eli Lilly
  • Merck
  • Novo Nordisk
  • Sanofi
Other prominent vendors
  • AbbVie
  • Actelion Pharmaceuticals
  • Adocia
  • Aegerion Pharmaceuticals
  • Akros Pharma
  • Alnylam Pharmaceuticals
  • Amarin
  • Amgen
  • Amicus Therapeutics
  • Arbutus Biopharma
  • Arena Pharmaceuticals
  • Astellas Pharma
  • Atheronova
  • Aurobindo Pharma
  • Baxalta
  • Belrose Pharma
  • BHV Pharma
  • Biocon
  • Biodel
  • BioMarin
  • Bionaturis
  • Biosidus
  • Biospherics
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Catabasis Pharmaceuticals
  • Cerenis Therapeutics
  • Chipscreen Biosciences
  • Cipla
  • CJ HealthCare
  • CKD Bio
  • Concord Biotech
  • ConjuChem
  • CureDM
  • CymaBay Therapeutics
  • Daewoong
  • Daiichi Sankyo
  • Dance Biopharm
  • DiaMedica
  • Diamyd Therapeutics
  • Diasome Pharmaceuticals
  • DiaVacs
  • Dong-A ST
  • Eisai
  • Elcelyx Therapeutics
  • Esperion Therapeutics
  • Exsulin
  • F. Hoffmann-La Roche
  • Gan & Lee Pharmaceuticals
  • Generex Biotechnology
  • Genfit
  • GlaxoSmithKline
  • HanAll BioPharma
  • Hanmi Pharmaceutical
  • Hua Medicine
  • Iltoo Pharma
  • Intarcia Therapeutics
  • InteKrin Therapeutics
  • Intrexon
  • Ionis Pharmaceuticals
  • Islet Sciences
  • ISU Abxis
  • Janssen Pharmaceuticals
  • Japan Tobacco
  • JCR Pharmaceuticals
  • JW Pharmaceuticals
  • Kadmon Pharmaceuticals
  • Kamada
  • KinDex Pharmaceuticals
  • Kissei
  • Kotobuki
  • Kowa Company
  • Laboratoires SMB
  • Lexicon Pharmaceuticals
  • Ligand Pharmaceuticals
  • Living Cell Technologies
  • Livzon
  • LIXTE Biotechnology
  • Lupin
  • MacroGenics
  • Madrigal Pharmaceuticals
  • MannKind Corporation
  • MedImmune
  • Melior Pharmaceuticals
  • Merrion Pharmaceuticals
  • Merz Pharmaceuticals
  • Metabolic Solutions Development
  • Mitsubishi Tanabe Pharma
  • Mylan
  • Neothetics
  • Neuraltus Pharmaceuticals
  • NGM Biopharmaceuticals
  • Norgine
  • Novartis
  • NuSirt Biopharma
  • Oramed
  • Orexigen Therapeutics
  • Osiris Therapeutics
  • Peptron
  • Perle Biosciences
  • Pfizer
  • PhaseBio Pharmaceuticals
  • Poxel
  • Protalix BioTherapeutics
  • Raptor
  • Recordati
  • Regeneron Pharmaceuticals
  • REGENX BioSciences
  • REGiMMUNE
  • Rhythm Pharmaceuticals
  • Saniona
  • Santaris Pharma
  • Sanwa Kagaku Kenkyusho
  • Serometrix
  • Shionogi
  • Shire
  • Sigma-Tau
  • Sirona Biochem
  • Strongbridge Biopharma
  • Sun Pharma
  • Takeda Pharmaceuticals
  • Teva
  • Thera Technologies
  • Theracos
  • Toleranzia
  • Tolerion
  • Torrent Pharmaceuticals
  • Transition Therapeutics
  • UCB
  • Utrecht Holdings
  • VeroScience
  • Vivus
  • vTv Therapeutics
  • XBiotech
  • Xeris Pharmaceuticals
  • XOMA
  • Zafgen
  • Zydus Cadila
Market driver
  • Change in patient preference
  • For a full, detailed list, view our report
Market challenge
  • Complex storage conditions and distribution policies for insulin
  • For a full, detailed list, view our report
Market trend
  • Focus on oral insulin therapies
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Diabetic Therapeutic Market 2017-2021

Technavio recognizes the following companies as the key players in the global diabetic therapeutic market: AstraZeneca, Eli Lilly, Merck, Novo Nordisk, and Sanofi.

Other Prominent Vendors in the market are: AbbVie, Actelion Pharmaceuticals, Adocia, Aegerion Pharmaceuticals, Akros Pharma, Alnylam Pharmaceuticals, Amarin, Amgen, Amicus Therapeutics, Arbutus Biopharma, Arena Pharmaceuticals, Astellas Pharma, Atheronova, Aurobindo Pharma, Baxalta, Belrose Pharma, BHV Pharma, Biocon, Biodel, BioMarin, Bionaturis, Biosidus, Biospherics, Boehringer Ingelheim, Bristol-Myers Squibb, Catabasis Pharmaceuticals, Cerenis Therapeutics, Chipscreen Biosciences, Cipla, CJ HealthCare, CKD Bio, Concord Biotech, ConjuChem, CureDM, CymaBay Therapeutics, Daewoong, Daiichi Sankyo, Dance Biopharm, DiaMedica, Diamyd Therapeutics, Diasome Pharmaceuticals, DiaVacs, Dong-A ST, Eisai, Elcelyx Therapeutics, Esperion Therapeutics, Exsulin, F. Hoffmann-La Roche, Gan & Lee Pharmaceuticals, Generex Biotechnology, Genfit, GlaxoSmithKline, HanAll BioPharma, Hanmi Pharmaceutical, Hua Medicine, Iltoo Pharma, Intarcia Therapeutics, InteKrin Therapeutics, Intrexon, Ionis Pharmaceuticals, Islet Sciences, ISU Abxis, Janssen Pharmaceuticals, Japan Tobacco, JCR Pharmaceuticals, JW Pharmaceuticals, Kadmon Pharmaceuticals, Kamada, KinDex Pharmaceuticals, Kissei, Kotobuki, Kowa Company, Laboratoires SMB, Lexicon Pharmaceuticals, Ligand Pharmaceuticals, Living Cell Technologies, Livzon, LIXTE Biotechnology, Lupin, MacroGenics, Madrigal Pharmaceuticals, MannKind Corporation, MedImmune, Melior Pharmaceuticals, Merrion Pharmaceuticals, Merz Pharmaceuticals, Metabolic Solutions Development, Mitsubishi Tanabe Pharma, Mylan, Neothetics, Neuraltus Pharmaceuticals, NGM Biopharmaceuticals, Norgine, Novartis, NuSirt Biopharma, Oramed, Orexigen Therapeutics, Osiris Therapeutics, Peptron, Perle Biosciences, Pfizer, PhaseBio Pharmaceuticals, Poxel, Protalix BioTherapeutics, Raptor, Recordati, Regeneron Pharmaceuticals, REGENX BioSciences, REGiMMUNE, Rhythm Pharmaceuticals, Saniona, Santaris Pharma, Sanwa Kagaku Kenkyusho, Serometrix, Shionogi, Shire, Sigma-Tau, Sirona Biochem, Strongbridge Biopharma, Sun Pharma, Takeda Pharmaceuticals, Teva, Thera Technologies, Theracos, Toleranzia, Tolerion, Torrent Pharmaceuticals, Transition Therapeutics, UCB, Utrecht Holdings, VeroScience, Vivus, vTv Therapeutics, XBiotech, Xeris Pharmaceuticals, XOMA, Zafgen, and Zydus Cadila.

Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is focus on oral insulin therapies. Regular insulin treatment is the only cure for type 1 diabetes since the insulin-producing beta cells can no longer produce enough insulin. In type 2 diabetes, insulin is administered when options such as diet, exercise, and oral antidiabetic drugs fail to maintain optimal blood glucose levels. Injections commonly deliver insulin through the subcutaneous tissues.”

According to the report, one of the major drivers for this market is change in patient preference. Earlier days, the treatment for diabetes was more popular in hospitals where an endocrinologist or a dietician guided the individuals in type 1 diabetes management. Though there were fruitful results achieved, there were some issues like long waiting times leading to crowding, limited visiting slots, high consultation fees, and non-availability of devices stock have made people to look for alternatives. Due to these reasons, the individuals had to revisit the hospitals repeatedly to get the check-up done. This looked favorable from the view of hospitals as they had high demand.

Further, the report states that one of the major factors hindering the growth of this market is complex storage conditions and distribution policies for insulin. Besides the restricted affordability and accessibility of insulin-based disease management, insulin treatment also suffers from poor storage and distribution policies. Inadequate distribution policies and lack of a centralized supply chain lead to intra-country variability in pricing. A heavy tax on insulin delivery devices such as syringes also hinders effective disease management despite insulin availability.

Companies Mentioned

AstraZeneca, Eli Lilly, Merck, Novo Nordisk, Sanofi, AbbVie, Actelion Pharmaceuticals, Adocia, Aegerion Pharmaceuticals, Akros Pharma, Alnylam Pharmaceuticals, Amarin, Amgen, Amicus Therapeutics, Arbutus Biopharma, Arena Pharmaceuticals, Astellas Pharma, Atheronova, Aurobindo Pharma, Baxalta, Belrose Pharma, BHV Pharma, Biocon, Biodel, BioMarin, Bionaturis, Biosidus, Biospherics, Boehringer Ingelheim, Bristol-Myers Squibb, Catabasis Pharmaceuticals, Cerenis Therapeutics, Chipscreen Biosciences, Cipla, CJ HealthCare, CKD Bio, Concord Biotech, ConjuChem, CureDM, CymaBay Therapeutics, Daewoong, Daiichi Sankyo, Dance Biopharm, DiaMedica, Diamyd Therapeutics, Diasome Pharmaceuticals, DiaVacs, Dong-A ST, Eisai, Elcelyx Therapeutics, Esperion Therapeutics, Exsulin, F. Hoffmann-La Roche, Gan & Lee Pharmaceuticals, Generex Biotechnology, Genfit, GlaxoSmithKline, HanAll BioPharma, Hanmi Pharmaceutical, Hua Medicine, Iltoo Pharma, Intarcia Therapeutics, InteKrin Therapeutics, Intrexon, Ionis Pharmaceuticals, Islet Sciences, ISU Abxis, Janssen Pharmaceuticals, Japan Tobacco, JCR Pharmaceuticals, JW Pharmaceuticals, Kadmon Pharmaceuticals, Kamada, KinDex Pharmaceuticals, Kissei, Kotobuki, Kowa Company, Laboratoires SMB, Lexicon Pharmaceuticals, Ligand Pharmaceuticals, Living Cell Technologies, Livzon, LIXTE Biotechnology, Lupin, MacroGenics, Madrigal Pharmaceuticals, MannKind Corporation, MedImmune, Melior Pharmaceuticals, Merrion Pharmaceuticals, Merz Pharmaceuticals, Metabolic Solutions Development, Mitsubishi Tanabe Pharma, Mylan, Neothetics, Neuraltus Pharmaceuticals, NGM Biopharmaceuticals, Norgine, Novartis, NuSirt Biopharma, Oramed, Orexigen Therapeutics, Osiris Therapeutics, Peptron, Perle Biosciences, Pfizer, PhaseBio Pharmaceuticals, Poxel, Protalix BioTherapeutics, Raptor, Recordati, Regeneron Pharmaceuticals, REGENX BioSciences, REGiMMUNE, Rhythm Pharmaceuticals, Saniona, Santaris Pharma, Sanwa Kagaku Kenkyusho, Serometrix, Shionogi, Shire, Sigma-Tau, Sirona Biochem, Strongbridge Biopharma, Sun Pharma, Takeda Pharmaceuticals, Teva, Thera Technologies, Theracos, Toleranzia, Tolerion, Torrent Pharmaceuticals, Transition Therapeutics, UCB, Utrecht Holdings, VeroScience, Vivus, vTv Therapeutics, XBiotech, Xeris Pharmaceuticals, XOMA, Zafgen, Zydus Cadila.

  • Executive summary
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
  • Disease overview: Diabetes
    • Table Types of diabetes
    • Diagnosis of diabetes
      • Table Diagnosis of diabetes
    • Complications associated with high blood glucose levels
  • Pipeline portfolio
    • Table Market share of pipeline molecules
    • Pipeline for new drug application (NDA) filings
      • Table NDA filings: Global diabetic therapeutic market
    • Pipeline for Phase III molecules
      • Table Phase III pipeline portfolio: Global diabetic therapeutic market
    • Pipeline for Phase II molecules
      • Table Phase II pipeline portfolio: Global diabetic therapeutic market
    • Pipeline for Phase I molecules
      • Table Phase I pipeline portfolio: Global diabetic therapeutic market
    • Pipeline for pre-clinical stage molecules
      • Table Pre-clinical pipeline portfolio: Global diabetic therapeutic market
    • Pipeline for discovery stage molecules
      • Table Pipeline portfolio for discovery stage molecules: Global diabetic therapeutic market
  • Market landscape
    • Market overview
      • Table Market snapshot of global diabetic therapeutic market 2016-2021
      • Table Overview of global diabetic therapeutic market 2016-2021
      • Table Global diabetic therapeutic market 2016-2021 ($ billions)
      • Table Prospects of the global diabetic therapeutic market
      • Table Vendors' strategies and the un-addressed needs for global diabetic therapeutic market
      • Table Global diabetic therapeutic market snapshot: Developed and emerging markets 2016
      • Table Factors affecting the insulin therapies
      • Table Global diabetic therapeutic market: Present and outlook and its impact
    • Five forces analysis
      • Table Five forces analysis
  • Overview of marketed products
    • Synopsis of key diabetic drugs
      • Table Information on key marketed diabetic drugs
    • Marketed product profiles
      • Table Product profiles of marketed products: Standard insulin therapies
      • Table Product profiles for marketed products: Non-insulin therapies - DPP-4 class
      • Table Product profiles for marketed products: Non-insulin therapies - GLP-1 class
      • Table Product profiles for marketed products: Non-insulin therapies - SGLT2s class
  • Market segmentation by type of disease
    • Table Segmentation of global diabetic therapeutic market by type of disease (2016)
    • Global type 1 diabetes market
      • Table Market overview of global type 1 diabetes market 2016-2021
      • Table Opportunity analysis of global type 1 diabetes market
      • Table Global type 1 diabetes market 2016-2021 ($ billions)
    • Global type 2 diabetes market
      • Table Market overview of global type 2 diabetes market 2016-2021
      • Table Opportunity analysis of global type 2 diabetes market
      • Table Global type 2 diabetes market 2016-2021 ($ billions)
    • Global gestational diabetes market
      • Table Global gestational diabetes market 2016-2021 ($ billions)
  • Market segmentation by drug class
    • Table Overview of global diabetic therapeutic market by drug class, 2016
    • Insulin therapies
    • Non-insulin therapies
  • Geographical segmentation
    • Table Snapshot of global diabetic therapeutics market by geography
    • Table Global diabetes therapeutics market segmentation by region: Market growth lifecycle analysis 2016
    • Table Diabetic therapeutic market revenue by geography 2016-2021 ($ billions)
    • Diabetic therapeutic market in Americas
      • Table Overview of diabetic therapeutic market in Americas
      • Table Diabetic therapeutic market in Americas 2016-2021 ($ billions)
    • Diabetic therapeutic market in US
      • Table Overview of diabetic therapeutic market in US
      • Table Opportunity analysis: Diabetic therapeutic market in US
      • Table PESTLE analysis: Diabetic therapeutic market in US
    • Diabetic therapeutic market in EMEA
      • Table Overview of diabetic therapeutic market in EMEA
      • Table Diabetic therapeutic market in EMEA 2016-2021 ($ billions)
      • Table Share of diabetic therapeutic market in EMEA 2016
    • Diabetic therapeutic market in Europe
      • Table Overview of diabetic therapeutic market in Europe
      • Table Diabetic therapeutic market: Regional outlook of Europe, 2016 and 2021
      • Table Opportunity analysis: Diabetic therapeutic market in Europe
      • Table PESTLE analysis: Diabetic therapeutic market in Europe
    • Diabetic therapeutic market in Germany
      • Table Overview of diabetic therapeutic market in Germany
      • Table Opportunity analysis: Diabetic therapeutic market in Germany
    • Diabetic therapeutic market in UK
      • Table Overview of diabetic therapeutic market in UK
      • Table Opportunity analysis: Diabetic therapeutic market in UK
    • Diabetic therapeutic market in France
      • Table Overview of diabetic therapeutic market in France
      • Table Opportunity analysis: Diabetic therapeutic market in France
    • Diabetic therapeutic market in Italy
      • Table Overview of diabetic therapeutic market in Italy
      • Table Opportunity analysis: Diabetic therapeutic market in Italy
    • Diabetic therapeutic market in Spain
      • Table Overview of diabetic therapeutic market in Spain
      • Table Opportunity analysis: Diabetic therapeutic market in Spain
    • Diabetic therapeutic market in APAC
      • Table Overview of diabetic therapeutic market in APAC
      • Table Diabetic therapeutic market: Regional outlook, APAC, 2016 and 2021
      • Table Diabetic therapeutic market in APAC 2016-2021 ($ billions)
    • Diabetic therapeutic market in China
      • Table Overview of diabetic therapeutic market in China
      • Table Opportunity analysis: Diabetic therapeutic market in China
      • Table Pest analysis: Diabetic therapeutic market in China
    • Diabetic therapeutic market in India
      • Table Overview of diabetic therapeutic market in India
      • Table Opportunity analysis: Diabetic therapeutic market in India
      • Table PESTLE analysis: Diabetic therapeutic market in India
  • Market drivers
    • Table Impact of drivers and challenges in global diabetes therapeutic market
    • Change in patient preference
    • Focus on self-management of diabetes
    • The strong potential of biologics
    • Unmet medical needs and scope for DMDs
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Complex storage conditions and distribution policies for insulin
    • Unpredictable outcomes on human due to lack of predictable animal models
    • Gap in nation-level diabetes management plans
    • Rising concerns in the scientific community
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Table Impact of trends in global diabetic therapeutic market
    • Focus on oral insulin therapies
      • Table Oral insulin pipeline portfolio
    • Growing technological integration fueling the market growth
      • Table Key technological integrations
    • Focus on regenerative medicines
      • Table Regenerative medicines under development for the treatment of diabetes
    • Strong and diversified pipeline portfolio
  • Vendor landscape
    • Competitive scenario
      • Table Competitive structure analysis of global diabetic therapeutic market 2016
      • Table Top-selling diabetic therapeutics based on sales 2015 ($ billions)
    • Market analysis 2016
      • Table Geographical presence of key vendors
      • Table Competitive scenario: Global diabetic therapeutic market vendors 2016-2021
    • Upcoming vendors for oral insulin therapies
    • Oramed Pharmaceuticals
      • Table Oramed Pharmaceuticals: Pipeline products
    • Generex Biotechnology
    • Other prominent vendors
  • Key vendor analysis
    • Novo Nordisk
      • Table Novo Nordisk: Key products in diabetes market
      • Table Novo Nordisk: Profile
      • Table Novo Nordisk: Strength analysis
      • Table Novo Nordisk: Strategy assessment
      • Table Novo Nordisk: Opportunity assessment
    • Sanofi
      • Table Sanofi: Key product offerings in diabetes market
      • Table Sanofi: Profile
      • Table Sanofi: Strength analysis
      • Table Sanofi: Strategy assessment
      • Table Sanofi: Opportunity assessment
    • Merck
      • Table Merck: Profile
      • Table Merck: Strength analysis
      • Table Merck: Strategy assessment
      • Table Merck: Opportunity assessment
    • Eli Lilly
      • Table Eli Lilly: Top-selling diabetic drugs in 2015
      • Table Eli Lilly: Profile
      • Table Eli Lilly: Strategy assessment
      • Table Eli Lilly: Opportunity assessment
    • AstraZeneca
      • Table AstraZeneca: Top-selling diabetes drugs in 2015
      • Table AstraZeneca: Profile
      • Table AstraZeneca: Strength analysis
      • Table AstraZeneca: Strategy assessment
      • Table AstraZeneca: Opportunity assessment
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report